

# DR. JUSTIN RAYES, M.D.C.M.

Cardiologist—Specialist in Cardiovascular Disease and Clinical Research

justin.rayes@cardiolanaudiere.ca

| (514) 826-7881

| www.cardiolanaudiere.ca

---

## PROFILE

Dr. Justin Rayes graduated from McGill University's Faculty of Medicine in 2014. He continued his training in internal medicine at McGill University before completing his specialization in adult cardiology at the Université de Montréal in 2020.

Since then, he has practised as a cardiologist and echocardiographer at the Centre hospitalier de Lanaudière in Joliette. As the founder of the Clinique de Cardiologie Lanaudière and the Unité de Recherche Clinique Lanaudière, he divides his time among patient care, clinical research, medical education, and healthcare administration.

---

## CLINICAL INTERESTS

- Cardiometabolic health and cardiovascular prevention: dyslipidemia, hypertension, diabetes, obesity
  - Heart failure: mineralocorticoid receptor modulators, immunomodulation
  - Integration of artificial intelligence into clinical practice
- 

## CLINICAL EXPERIENCE

**SINCE MARCH 2025,**

### **CLINIQUE DE CARDIOLOGIE LANAUDIÈRE : FOUNDER AND ATTENDING CARDIOLOGIST**

- Provides consultations in coronary artery disease, atrial fibrillation, heart failure and other cardiovascular conditions
- Performs ECGs, exercise stress tests, echocardiograms, Holter monitoring and ambulatory blood pressure monitoring
- Follows and programs cardiac implantable devices (pacemakers, ICDs and CRT devices).

**SINCE 2020,**

### **SANTÉ QUÉBEC LANAUDIÈRE : CARDIOLOGIST AND ECHOCARDIOGRAPHER CLINICAL PROFESSOR UNIVERSITÉ LAVAL**

- Intensive care, emergency and inpatient cardiology coverage
- Coronary care unit management
- Performs and supervises transthoracic and transesophageal echocardiography.

---

## EDUCATION

|           |                                                              |
|-----------|--------------------------------------------------------------|
| 2017–2020 | Adult Cardiology Residency<br>Université de Montréal         |
| 2014–2017 | Internal Medicine Residency<br>McGill University, Montréal   |
| 2014 —    | Doctor of Medicine (M.D.C.M.)<br>McGill University, Montréal |

---

## CERTIFICATION

- FRCPC — Adult Cardiology (2020)
  - FRCPC — Internal Medicine (2018)
  - ABIM — Cardiovascular Disease (2020)
  - ABIM — Internal Medicine (2018)
  - CMQ — License to Practice Medicine (Québec) (2018)
  - USMLE — Steps 1, 2, 3 (2013–2017)
  - MCCQE — Steps 1 and 2 (2014–2016)
- 

## RESEARCH EXPERIENCE

### Principal Investigator

- **ATTAIN-Outcomes (2025)**—Phase III, randomized, double-blind clinical trial evaluating the effect of orforglipron (an oral, non-peptide GLP-1 receptor agonist), compared with placebo, on reducing major adverse cardiovascular events in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease.
- **BalanceD-HF (2025)**—Phase III, randomized, double-blind clinical trial evaluating the effect of the combination of balcinrenone (a mineralocorticoid receptor modulator) and dapagliflozin (an SGLT2 inhibitor), compared with dapagliflozin alone, on reducing heart failure events and cardiovascular mortality in patients with heart failure and renal dysfunction

### Sub-Investigator

- **COLCOT-T2D (2024)** — Randomized clinical trial evaluating the combined effect of colchicine and aspirin on cardiovascular outcomes in patients with type 2 diabetes and no prior history of cardiovascular disease.
- **Dal-GenE-2 (2024)**—Phase III, randomized, controlled clinical trial evaluating the efficacy of **dalcetrapib** in reducing major adverse cardiovascular events in post–acute coronary syndrome patients carrying the AA genotype of the ADCY9 gene.
- **OCEAN(a) Outcomes (2023)**—International Phase III, randomized, double-blind clinical trial evaluating the effect of olpasiran, an RNA interference (RNAi) therapeutic, on major adverse cardiovascular events in patients with elevated lipoprotein(a) [Lp(a)].
- **BRAVE (2023)** — Randomized, controlled feasibility study evaluating the impact of bariatric surgery on reducing cardiovascular events in patients with obesity at high cardiovascular risk.

---

## CLINICAL RESEARCH TRAINING

- Good Clinical Practice (ICH E6(R3))—Syneos Health (2025)
  - Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) (2025)
  - Good Clinical Practice (ICH E6(R2))—CITI/CISSS de Lanaudière (2024)
  - Health Canada Food and Drug Regulations—Part C, Division 5 (2024)
  - Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects (2023)
  - Research Ethics—Ministère de la Santé et des Services sociaux (MSSS) (2023)
- 

## ADMINISTRATIVE LEADERSHIP

### Council of Physicians, Dentists and Pharmacists (CMDP)—Santé Québec Lanaudière

- Executive Committee Member (2022–2025)
  - Medical Advisor—2022–2023
  - Secretary General—2023–2024
  - Vice-president—2024–2025
- Active involvement in medical governance, policy development and review, strategic collaboration with executive leadership, and continuous quality improvement initiatives.

### Hospital Patient Flow Coordinator—Santé Québec Lanaudière (since 2022)

Responsible for optimizing inpatient care efficiency, including patient flow, discharge planning, clinical pathway optimization, and interdisciplinary collaboration

---

## MEDICAL EDUCATION AND TEACHING

### Clinical Professor Université Laval

- Supervision of cardiology and family medicine residents
  - Clinical supervision and mentorship of undergraduate medical students
  - Bedside teaching focused on the development of technical skills and clinical reasoning
- 

## MEDICO-LEGAL ACTIVITY

### Ducore Expertise /Expert Cardiologist / *Since October 2025*

- Conduct independent medical assessments in cardiology and internal medicine, including medico-legal evaluations and disability cases.
  - Review clinical records and provide evidence-based expert opinions.
- 

## LANGUAGES

- English—Native proficiency
- French—Native proficiency